Reviva Pharmaceuticals Holdings, Inc.
$0.91
▼
-11.08%
2026-04-21 09:14:01
www.revivapharma.com
NCM: RVPH
Explore Reviva Pharmaceuticals Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$10.89 M
Current Price
$0.91
52W High / Low
$23.2 / $0.59
Stock P/E
—
Book Value
$1.47
Dividend Yield
—
ROCE
-233.59%
ROE
-4.2%
Face Value
—
EPS
$-5
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
0.64
Debt / Equity
4.71
Current Ratio
2.08
Quick Ratio
2.08
Forward P/E
-0.93
Price / Sales
—
Enterprise Value
$-4.16 M
EV / EBITDA
—
EV / Revenue
—
Rating
Buy
Target Price
$58.2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 2. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
| 3. | Incyte Corporation | $97.69 | 15.26 | $19.46 B | — | 24.67% | 29.87% | $112.29 / $56.13 | $26.04 |
| 4. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 5. | Iovance Biotherapeutics, Inc. | $3.78 | — | $1.56 B | — | -51.39% | -55.5% | $5.63 / $1.64 | $1.7 |
| 6. | Xenon Pharmaceuticals Inc. | $57.09 | — | $5.48 B | — | -63.09% | -51.76% | $63.95 / $28.19 | $7.27 |
| 7. | Entrada Therapeutics, Inc. | $13.56 | — | $535.6 M | — | -44.74% | -39.13% | $14.49 / $4.93 | $8.5 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.56 M | -4.03 M | -6.07 M | -6.54 M | -6.28 M | — |
| Net Profit | -3.37 M | -4.01 M | -6.05 M | -6.43 M | -6.26 M | — |
| EPS in Rs | -0.26 | -0.31 | -0.47 | -0.5 | -0.49 | -5 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -20.2 M | -30.8 M | -39.5 M | -28.23 M |
| Net Profit | -19.86 M | -29.92 M | -39.26 M | -28.26 M |
| EPS in Rs | -1.55 | -2.34 | -3.06 | -2.21 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 15.92 M | 15.5 M | 23.7 M | 18.92 M |
| Total Liabilities | 7.28 M | 14.69 M | 17.98 M | 10.53 M |
| Equity | 8.65 M | 0.81 M | 5.72 M | 8.39 M |
| Current Assets | 15.1 M | 14.68 M | 23.7 M | 18.92 M |
| Current Liabilities | 7.28 M | 14.6 M | 17.18 M | 9.96 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -24.59 M | -33.54 M | -28.32 M | -18.96 M |
| Investing CF | — | — | — | — |
| Financing CF | 25.56 M | 23.65 M | 33.17 M | 7.79 M |
| Free CF | -24.59 M | -33.54 M | -28.32 M | -18.96 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 23.79% | -38.92% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-03-09 | 1:0.05 |